Continuing maintenance therapy with lenalidomide beyond 2 years after initial treatment did not improve overall survival in standard-risk myeloma.

The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.

Olomorasib earned breakthrough therapy status as a monotherapy for adults with previously treated, KRAS G12C-mutant advanced pancreatic cancer.

Gedatolisib plus fulvestrant, with or without palbociclib, has been added to the NCCN Guidelines for select patients with previously treated breast cancer.

First-line tislelizumab plus gemcitabine produced durable responses in platinum-ineligible locally advanced or metastatic urothelial carcinoma.

Obinutuzumab plus zanubrutinib produced high complete response rates with manageable toxicity in older patients with previously untreated mantle cell lymphoma.

Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.

A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.